| Report ID | 277590 |
| Drug Identification Number | 02338327 |
| Brand name | ADCIRCA |
| Common or Proper name | tadalafil tablets |
| Company Name | ELI LILLY CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | TADALAFIL |
| Strength(s) | 20MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | Carton containing 56 tablets in blister packaging |
| ATC code | G04BE |
| ATC description | OTHER UROLOGICALS, INCL ANTISPASMODICS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2026-05-29 |
| Actual discontinuation date | |
| Remaining supply date | 2026-05-29 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Based on current utilization, Lilly has supply to meet the current Adcirca demand rate through the anticipated discontinuation date. Please note the anticipated remaining supply date may be impacted based on any changes in demand. Additionally, Lilly is proactively engaging with Apotex Inc as they market APO-TADALAFIL PAH in Canada, which is authorized by Health Canada and designated as bioequivalent with Adcrica. Apotex has confirmed their ability to support the market demand with Lilly’s discontinuation of Adcirca from the market. |
| Company comments | For any questions, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
| Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-02-06 | French | Compare |
| v1 | 2026-02-06 | English | Compare |
Showing 1 to 2 of 2